Ying-Hong Feng

Dr. Ying-Hong Feng is a researcher at the Uniformed Services University of the Health Sciences, affiliated with the School of Medicine and the Department of Pharmacology & Molecular Therapeutics. His research focuses on receptor structure-function, epigenome editing, and translational studies in neurodegenerative diseases, cancer, and cardiovascular disorders. He earned his M.D. from Wuhan University and a Ph.D. in Biochemistry from the University of Oxford, followed by postdoctoral training at the Cleveland Clinic Foundation.

Dr. Feng’s lab investigates three core areas: receptor dimerization in disease pathophysiology, translational research on neurodegeneration and cancer (focusing on gene splicing variants and exosome biology), and novel genome/epigenome editing technologies. His work spans basic mechanisms of receptor signaling to clinical applications in drug resistance and targeted therapies.

Publications highlight contributions to understanding P2X7 receptor variants in cancer, angiotensin receptor signaling in hypertension, and epigenetic manipulation in prostate cancer. Despite no listed awards, his consistent output demonstrates expertise in molecular mechanisms and translational medicine.

Lab activities include interdisciplinary collaborations on drug delivery systems (e.g., folate-targeted nanoparticles) and CRISPR-based epigenetic tools. While no grants or advising details are provided, his work underscores a focus on bridging basic science and clinical challenges in complex diseases.